EXHIBIT 1.1 3,000,000 Shares ANIKA THERAPEUTICS, INC. Common Stock Par Value $0.01 Per Share FORM OF UNDERWRITING AGREEMENT ------------------------------Anika Therapeutics Inc • November 10th, 1997 • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.2Employment Agreement • September 14th, 2009 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus • Massachusetts
CREDIT AGREEMENTCredit Agreement • October 27th, 2017 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This CREDIT AGREEMENT is entered into as of October 24, 2017, among ANIKA THERAPEUTICS, INC., a Massachusetts corporation (the “Borrower”), the Subsidiaries of the Borrower as are or may from time to time become parties to this Agreement as Subsidiary Guarantors (defined herein), the Lenders (defined herein), and BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and L/C Issuer.
SECOND AMENDMENT TO EXCLUSIVE DISTRIBUTION AGREEMENTExclusive Distribution Agreement • May 15th, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Anika Therapeutics, Inc. and American Stock Transfer & Trust Company as Rights Agent Shareholder Rights AgreementShareholder Rights Agreement • April 7th, 2008 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus • Massachusetts
Agreement, dated as of April 7, 2008, between Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and American Stock Transfer & Trust Company, a New York corporation (the “Rights Agent”).
EXHIBIT 10.2 ANIKA THERAPEUTICS, INC. CHANGE IN CONTROL, BONUS AND SEVERANCE AGREEMENT AGREEMENT made as of April 26, 2000 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts...Severance Agreement • August 14th, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
SECURITY AND PLEDGE AGREEMENTSecurity and Pledge Agreement • October 27th, 2017 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus
This SECURITY AND PLEDGE AGREEMENT (as amended, modified, extended, restated, renewed, replaced, or supplemented from time to time, this “Agreement”) is entered into as of October 24, 2017 among ANIKA THERAPEUTICS, INC., a Massachusetts corporation (the “Borrower”), the Subsidiaries of the Borrower identified as “Grantors” on the signature pages hereto and such other parties that may become Grantors hereunder after the date hereof (together with the Borrower, each individually a “Grantor”, and collectively, the “Grantors”) and BANK OF AMERICA, N.A., in its capacity as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties.
EXHIBIT 10.8 ANIKA THERAPEUTICS, INC. CHANGE IN CONTROL, BONUS AND SEVERANCE AGREEMENT AGREEMENT made as of April 26, 2000 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts...Severance Agreement • August 14th, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.13 ANIKA THERAPEUTICS, INC. CHANGE IN CONTROL, BONUS AND SEVERANCE AGREEMENT AGREEMENT made as of June 3, 1999 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts...And Severance Agreement • March 31st, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.31 ANIKA RESEARCH, INC. NON-DISCLOSURE AND NON-COMPETITION AGREEMENT I, Edward Ross, Jr., (the "Employee"), in consideration of my employment, the continuation of my employment and the salary and wages to be paid to me, do hereby agree with...Competition Agreement • April 2nd, 2001 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
June 15, 2001Letter Agreement • August 14th, 2001 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
andShareholder Rights Agreement • April 7th, 1998 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.7 ANIKA THERAPEUTICS, INC. CHANGE IN CONTROL, BONUS AND SEVERANCE AGREEMENT AGREEMENT made as of April 26, 2000 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts...Severance Agreement • August 14th, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.2 TERMINATION AGREEMENT AND MUTUAL RELEASE This Termination Agreement and Mutual Release ("Termination Agreement") is made by and between ZIMMER, INC., a Delaware corporation having its principal place of business at 345 East Main Street,...Termination Agreement and Mutual Release • November 14th, 2000 • Anika Therapeutics Inc • Biological products, (no disgnostic substances)
ANIKA THERAPEUTICS, INC. Form of Change in Control, Bonus and Severance AgreementAgreement • November 19th, 2004 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
AGREEMENT made as of October 6, 2004 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts (the “Company”), and Carol A. Toth, of East Walpole, Massachusetts (the “Executive”), an individual presently employed as the Senior Vice President Marketing and Business Development of the Company.
DIRECTOR INDEMNIFICATION AGREEMENTIndemnification Agreement • November 6th, 2014 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Indemnification Agreement (“Agreement”) is made as of November 5, 2014 by and between Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and ____________ (“Indemnitee”).
INCENTIVE STOCK OPTION AGREEMENT UNDER THE ANIKA THERAPEUTICS, INC. 2003 STOCK OPTION AND INCENTIVE PLANIncentive Stock Option Agreement • October 5th, 2004 • Anika Therapeutics Inc • Biological products, (no disgnostic substances)
Pursuant to the Anika Therapeutics, Inc. 2003 Stock Option Incentive Plan (the “Plan”) as amended through the date hereof, Anika Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $.01 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
EXHIBIT 10.26 ANIKA THERAPEUTICS, INC. NON-DISCLOSURE AND NON-COMPETITION AGREEMENT I, Charles H. Sherwood, (the "Employee"), in consideration of my employment, the continuation of my employment and the salary and wages to be paid to me, do hereby...Competition Agreement • April 2nd, 2001 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
ANIKA THERAPEUTICS, INC. EXECUTIVE RETENTION AGREEMENTExecutive Retention Agreement • March 16th, 2023 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and [David Colleran] (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of March 9th, 2020 (the “Effective Date”).
Fixed Dollar Accelerated Share Repurchase TransactionLetter Agreement • July 26th, 2019 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Transaction entered into between Morgan Stanley & Co. LLC (“MSCO”) and Anika Therapeutics, Inc. (“Issuer”) on the Trade Date specified below (the “Transaction”). This confirmation constitutes a “Confirmation” as referred to in the Agreement specified below.
CREDIT AGREEMENT Dated as of January 31, 2008 among ANIKA THERAPEUTICS, INC. as Borrower, ANIKA SECURITIES, INC. as a Guarantor,Credit Agreement • February 6th, 2008 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus • Massachusetts
CREDIT AGREEMENT (this “Agreement”) is entered into as of January 31, 2008 among ANIKA THERAPEUTICS, INC., a Massachusetts corporation (“Borrower”), ANIKA SECURITIES, INC., a Massachusetts securities corporation (“Anika Securities”), each lender from time to time party hereto (collectively, “Lenders” and individually, a “Lender”), and BANK OF AMERICA, N.A., as Administrative Agent.
andShareholder Rights Agreement • April 7th, 1998 • Anika Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
PLEDGE AGREEMENT ON A QUOTA OF FIDIA ADVANCED BIOPOLYMERS S.r.l.Pledge Agreement • May 10th, 2010 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus
THIS PLEDGE AGREEMENT is entered in Boston, Massachusetts (U.S.A.), on March 12, 2010, by ANIKA THERAPEUTICS, INC., a company duly incorporated under the laws of Massachusetts, whose registered office is at 32 Wiggins Avenue, Bedford, Massachusetts 01730 Italian tax code number 97542640152, acting by its legal representative Dr. Charles Sherwood (the “Pledgor”), in favor of BANK OF AMERICA, N.A., bank association, incorporated under the laws of United States of America, with legal office in North Tryon Street 100, Charlotte, North Carolina (U.S.A.) (“Bank of America”);
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2011 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus
THIS AMENDMENT NO. 1 (“Amendment No. 1”) to the EMPLOYMENT AGREEMENT (the “Agreement”) by and between Kevin Quinlan (the “Executive”) and Anika Therapeutics, Inc., a Massachusetts corporation (the “Corporation”), dated as of October 17, 2008, is made this 8th day of December, 2010.
STANDARD FORM LEASE EXTENSIONAnika Therapeutics Inc • April 2nd, 2001 • Biological products, (no disgnostic substances)
Portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(2). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed.Agreement and Plan of Merger • January 7th, 2020 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2014 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 22nd day of March, 2010 between Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and Sylvia Cheung (the “Executive”).
RESTRICTED STOCK AWARD AGREEMENT UNDER THE ANIKA THERAPEUTICS, INC. 2003 STOCK OPTION AND INCENTIVE PLANRestricted Stock Award Agreement • March 12th, 2008 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus
Pursuant to the Anika Therapeutics, Inc. 2003 Stock Option and Incentive Plan (the "Plan") as amended through the date hereof, Anika Therapeutics, Inc. (the "Company") hereby grants a Restricted Stock Award (an "Award") to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.01 per share (the "Stock") of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan.
Form of Change in Control, Bonus and Severance AgreementSeverance Agreement • July 12th, 2005 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus • Massachusetts
AGREEMENT made as of July 11, 2005 by and among Anika Therapeutics, Inc., a Massachusetts corporation with its principal place of business in Woburn, Massachusetts (the “Company”), and Kevin W. Quinlan, with his principal residence in Marblehead, MA, (the “Executive”), an individual presently employed as the Chief Financial Officer of the Company.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2014 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus
THIS AMENDMENT NO. 1 (“Amendment No. 1”) to the EMPLOYMENT AGREEMENT (the “Agreement”) by and between Sylvia Cheung (the “Executive”) and Anika Therapeutics, Inc., a Massachusetts corporation (the “Corporation”), dated as of March 22, 2010, is made this 8th day of December, 2010.
CUMMINGS PROPERTIES STANDARD FORM COMMERCIAL LEASEAnika Therapeutics Inc • April 2nd, 2001 • Biological products, (no disgnostic substances) • Massachusetts
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2011 • Anika Therapeutics Inc • Surgical & medical instruments & apparatus
THIS AMENDMENT NO. 1 (“Amendment No. 1”) to the EMPLOYMENT AGREEMENT (the “Agreement”) by and between William J. Mrachek (the “Executive”) and Anika Therapeutics, Inc., a Massachusetts corporation (the “Corporation”), dated as of September 10, 2009, is made this 8th day of December, 2010.
Farley White Wiggins, LLC c/o Farley White InterestsAnika Therapeutics, Inc. • February 24th, 2017 • Surgical & medical instruments & apparatus
This letter will confirm our understanding and agreement that, in order to correct a scrivener’s error, the phrase “From the sixth (6th) anniversary” in the fourth paragraph of the definition of Annual Base Rent in Article 1.1 of the Lease is deleted and replaced with the phrase “From the fifth (5th) anniversary”.
AMENDMENT TO THE LEASE AGREEMENT (Reg.ne 39 series 3T) By and betweenThe Lease Agreement • May 3rd, 2016 • Anika Therapeutics, Inc. • Surgical & medical instruments & apparatus
FIDIA FARMACEUTICI S.P.A. with legal domicile in Abano Terme (PD) via Ponte della Fabbrica 3/A, Italy, VAT Code 00204260285 (hereinafter “Fidia”)
Anika Therapeutics, Inc. Bedford, Massachusetts 01730Anika Therapeutics, Inc. • March 2nd, 2020 • Surgical & medical instruments & apparatus • Massachusetts
On behalf of Anika Therapeutics, Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the principal terms of the compensation package to be provided to you by the Company for your services as Interim Chief Executive Officer of the Company (“Interim CEO”), which appointment was effective as of February 10, 2020 and will continue through the period set forth in Section 2 (the “Term”).
